Ratings by B.Riley (Kalpit Patel)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/4/2026 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 2/4/2026 | Journey Medical Corp. | DERM | Maintain | Buy (N/A) |
|
Details | ||
| 12/22/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 10/23/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 7/30/2025 | Journey Medical Corp. | DERM | Maintain | Buy (N/A) |
|
Details | ||
| 6/3/2025 | Kymera Therapeutics | KYMR | Upgrade | Buy (Neutral) |
29.64 (83.49) |
181.68% | Details | |
| 5/21/2025 | Viridian Therapeutic | VRDN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/12/2025 | Kymera Therapeutics | KYMR | Maintain | Neutral (N/A) |
|
Details | ||
| 5/9/2025 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 5/7/2025 | Viridian Therapeutic | VRDN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/7/2025 | Corbus Pharmaceuticals | CRBP | Maintain | Buy (N/A) |
|
Details | ||
| 5/2/2025 | Bicycle Therapeutics | BCYC | Maintain | Neutral (N/A) |
|
Details | ||
| 3/20/2025 | ArriVent BioPharma | AVBP | New Coverage | Buy (N/A) |
19.50 (23.43) |
20.15% | Details | |
| 3/5/2025 | Rigel Pharmaceuticals | RIGL | Maintain | Neutral (N/A) |
|
Details | ||
| 3/3/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2025 | Geron Corporation | GERN | Downgrade | Neutral (Buy) |
2.37 (1.53) |
-35.44% | Details | |
| 2/18/2025 | Geron Corporation | GERN | Maintain | Buy (N/A) |
|
Details | ||
| 1/29/2025 | Foghorn Therapeutics | FHTX | New Coverage | Buy (N/A) |
4.10 (5.78) |
40.98% | Details | |
| 12/30/2024 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 12/16/2024 | Bicycle Therapeutics | BCYC | Maintain | Neutral (N/A) |
|
Details | ||
| 12/13/2024 | Bicycle Therapeutics | BCYC | Maintain | Neutral (N/A) |
|
Details | ||
| 12/10/2024 | Rigel Pharmaceuticals | RIGL | Maintain | Neutral (N/A) |
|
Details | ||
| 12/6/2024 | Rigel Pharmaceuticals | RIGL | Maintain | Neutral (N/A) |
|
Details | ||
| 11/18/2024 | X4 Pharmaceuticals | XFOR | Maintain | Neutral (N/A) |
|
Details | ||
| 11/18/2024 | Journey Medical Corp. | DERM | Maintain | Buy (N/A) |
|
Details | ||
| 11/1/2024 | Kymera Therapeutics | KYMR | Maintain | Neutral (N/A) |
|
Details | ||
| 10/24/2024 | Bicycle Therapeutics | BCYC | Maintain | Neutral (N/A) |
|
Details | ||
| 10/22/2024 | Geron Corporation | GERN | Maintain | Buy (Buy) |
|
Details | ||
| 10/14/2024 | Longboard Pharmaceuticals Inc | LBPH | Downgrade | Neutral (Buy) |
38.90 (59.98) |
54.19% | Details | |
| 10/9/2024 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (Buy) |
|
Details | ||
| 9/27/2024 | Ovid Therapeutics Inc | OVID | Maintain | Buy (N/A) |
|
Details | ||
| 9/20/2024 | Corbus Pharmaceuticals | CRBP | Maintain | Buy (N/A) |
|
Details | ||
| 9/11/2024 | Viridian Therapeutic | VRDN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/13/2024 | Journey Medical Corp. | DERM | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2024 | Geron Corporation | GERN | Maintain | Buy (N/A) |
|
Details | ||
| 8/7/2024 | Rigel Pharmaceuticals | RIGL | Maintain | Neutral (N/A) |
|
Details | ||
| 8/7/2024 | Bicycle Therapeutics | BCYC | Downgrade | Neutral (Buy) |
22.71 (5.19) |
-77.15% | Details | |
| 8/5/2024 | Longboard Pharmaceuticals Inc | LBPH | Maintain | Buy (N/A) |
|
Details | ||
| 7/24/2024 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 7/9/2024 | Kymera Therapeutics | KYMR | Maintain | Neutral (N/A) |
|
Details | ||
| 6/26/2024 | Corbus Pharmaceuticals | CRBP | New Coverage | Buy (N/A) |
43.51 (8.01) |
-81.59% | Details | |
| 6/17/2024 | Ovid Therapeutics Inc | OVID | Maintain | Buy (N/A) |
|
Details | ||
| 6/10/2024 | Longboard Pharmaceuticals Inc | LBPH | Maintain | Buy (N/A) |
|
Details | ||
| 5/14/2024 | Allogene | ALLO | Maintain | Buy (N/A) |
|
Details | ||
| 5/9/2024 | Viridian Therapeutic | VRDN | Downgrade | Neutral (Buy) |
15.14 (28.34) |
87.19% | Details | |
| 4/30/2024 | Ovid Therapeutics Inc | OVID | New Coverage | Buy (N/A) |
3.10 (0.51) |
-83.55% | Details | |
| 3/21/2024 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 2/26/2024 | Rigel Pharmaceuticals | RIGL | Maintain | Neutral (N/A) |
|
Details | ||
| 2/23/2024 | Kymera Therapeutics | KYMR | Maintain | Neutral (N/A) |
|
Details | ||
| 1/12/2024 | Longboard Pharmaceuticals Inc | LBPH | Maintain | Buy (N/A) |
|
Details | ||
| 1/5/2024 | Allogene | ALLO | Maintain | Buy (N/A) |
|
Details | ||
| 12/12/2023 | X4 Pharmaceuticals | XFOR | Downgrade | Neutral (Buy) |
0.61 (3.76) |
516.39% | Details | |
| 12/7/2023 | Journey Medical Corp. | DERM | Maintain | Buy (N/A) |
|
Details | ||
| 11/17/2023 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2023 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 11/2/2023 | Kymera Therapeutics | KYMR | Maintain | Neutral (N/A) |
|
Details | ||
| 10/9/2023 | Mirati Therapeutics | MRTX | Downgrade | Neutral (Buy) |
60.20 (58.70) |
-2.49% | Details | |
| 10/9/2023 | Mirati Therapeutics | MRTX | Downgrade | Neutral (Buy) |
60.20 (58.70) |
-2.49% | Details | |
| 10/6/2023 | Mirati Therapeutics | MRTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/26/2023 | Verastem | VSTM | New Coverage | Buy (N/A) |
9.37 (6.38) |
-31.91% | Details | |
| 9/11/2023 | Bicycle Therapeutics | BCYC | Upgrade | Buy (N/A) |
20.95 (5.19) |
-75.23% | Details | |
| 9/11/2023 | Bicycle Therapeutics | BCYC | Upgrade | Buy (Neutral) |
20.95 (5.19) |
-75.23% | Details | |
| 8/30/2023 | X4 Pharmaceuticals | XFOR | New Coverage | Buy (N/A) |
1.31 (3.76) |
187.02% | Details | |
| 8/9/2023 | Mirati Therapeutics | MRTX | Upgrade | Buy (Neutral) |
27.80 (58.70) |
111.15% | Details | |
| 7/24/2023 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 7/12/2023 | Journey Medical Corp. | DERM | Maintain | Buy (N/A) |
|
Details | ||
| 5/23/2023 | Journey Medical Corp. | DERM | Maintain | Buy (N/A) |
|
Details | ||
| 4/27/2023 | Longboard Pharmaceuticals Inc | LBPH | New Coverage | Buy (N/A) |
7.34 (38.90) |
429.97% | Details | |
| 3/1/2023 | Allogene | ALLO | Maintain | Buy (N/A) |
|
Details | ||
| 1/23/2023 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/10/2023 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 1/9/2023 | Geron Corporation | GERN | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2022 | Kymera Therapeutics | KYMR | Maintain | Neutral (N/A) |
|
Details | ||
| 12/8/2022 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/30/2022 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2022 | IN8bio Inc. | INAB | Downgrade | Neutral (Buy) |
1.65 (1.72) |
4.24% | Details | |
| 11/7/2022 | Kymera Therapeutics | KYMR | Maintain | Neutral (N/A) |
|
Details | ||
| 11/7/2022 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 10/28/2022 | Mirati Therapeutics | MRTX | New Coverage | Neutral (N/A) |
66.38 (58.70) |
-11.57% | Details | |
| 9/22/2022 | Allogene | ALLO | Maintain | Buy (N/A) |
|
Details | ||
| 8/16/2022 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 8/3/2022 | Rigel Pharmaceuticals | RIGL | Maintain | Neutral (N/A) |
|
Details | ||
| 7/28/2022 | Syndax Pharmaceuticals | SNDX | New Coverage | Buy (N/A) |
21.23 (12.57) |
-40.79% | Details | |
| 7/28/2022 | Geron Corporation | GERN | New Coverage | Buy (N/A) |
1.97 (1.53) |
-22.34% | Details | |
| 7/19/2022 | Entera Bio | ENTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/23/2022 | Viridian Therapeutic | VRDN | New Coverage | Buy (N/A) |
10.63 (28.34) |
166.6% | Details | |
| 6/9/2022 | Rigel Pharmaceuticals | RIGL | Maintain | Neutral (N/A) |
|
Details | ||
| 6/7/2022 | Vincerx Pharma | VINC | Maintain | Buy (N/A) |
|
Details | ||
| 5/4/2022 | Kymera Therapeutics | KYMR | Maintain | Neutral (N/A) |
|
Details | ||
| 4/13/2022 | Bicycle Therapeutics | BCYC | Downgrade | Neutral (Buy) |
28.81 (5.19) |
-81.99% | Details | |
| 3/23/2022 | Rigel Pharmaceuticals | RIGL | New Coverage | Neutral (N/A) |
3.34 (28.87) |
764.37% | Details | |
| 3/2/2022 | Bicycle Therapeutics | BCYC | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2022 | Allogene | ALLO | Maintain | Buy (N/A) |
|
Details | ||
| 1/24/2022 | Magenta Therapeutics | MGTA | Maintain | Buy (N/A) |
|
Details | ||
| 1/24/2022 | IN8bio Inc. | INAB | Maintain | Buy (N/A) |
|
Details | ||
| 1/24/2022 | Entera Bio | ENTX | Maintain | Buy (N/A) |
|
Details | ||
| 11/8/2021 | Magenta Therapeutics | MGTA | Maintain | Buy (N/A) |
|
Details | ||
| 10/8/2021 | Bicycle Therapeutics | BCYC | Maintain | Buy (N/A) |
|
Details | ||
| 10/8/2021 | Allogene | ALLO | Maintain | Buy (N/A) |
|
Details | ||
| 10/7/2021 | Entera Bio | ENTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/30/2021 | Kymera Therapeutics | KYMR | New Coverage | Neutral (N/A) |
60.82 (29.64) |
-51.27% | Details | |
| 9/30/2021 | Bicycle Therapeutics | BCYC | New Coverage | Buy (N/A) |
41.37 (5.19) |
-87.45% | Details | |
| 9/9/2021 | Forte Biosciences Inc. | FBRX | Downgrade | Neutral (Buy) |
4.19 (28.76) |
586.4% | Details | |
| 9/3/2021 | Forte Biosciences Inc. | FBRX | Downgrade | Neutral (Buy) |
29.92 (28.76) |
-3.88% | Details | |
| 8/25/2021 | Vincerx Pharma | VINC | New Coverage | Buy (N/A) |
14.47 (0.10) |
-99.31% | Details | |
| 8/23/2021 | IN8bio Inc. | INAB | New Coverage | Buy (N/A) |
7.88 (1.72) |
-78.17% | Details | |
| 7/22/2021 | Magenta Therapeutics | MGTA | Maintain | Buy (N/A) |
|
Details | ||
| 6/24/2021 | Entera Bio | ENTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/16/2021 | Entera Bio | ENTX | New Coverage | Buy (N/A) |
3.74 (1.25) |
-66.58% | Details | |
| 5/18/2021 | Magenta Therapeutics | MGTA | New Coverage | Buy (N/A) |
11.06 (0.70) |
-93.67% | Details | |
| 5/14/2021 | Allogene | ALLO | New Coverage | Buy (N/A) |
27.95 (2.30) |
-91.77% | Details | |
| 5/14/2021 | Forte Biosciences Inc. | FBRX | New Coverage | Buy (N/A) |
33.93 (28.76) |
-15.24% | Details |
